Vol. 5 • Issue 1 • Page 33
To read the full article, click here.
1. American Heart Association 2008 Update. Available at: http://www.americanheart.org/downloadable/heart/1200082005246HS_Stats%202008.final.pdf
2. Muller JE, et. al. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989, 79:733-743
3. American Heart Association Available at: http://www.strokeassociation.org/presenter.jhtml?identifier=4716
4. Leon AS, Wilmore JH, Ewy GA, Rankinen T, Rao DC, Skinner JS, et al. Endurance exercise training reduces lipoprotein-associated phospholipase A2 (LP-PLA2) in young white adults: the HERITAGE family study. Med Sci Sports Exerc. 2007;39(suppl):S312. Identifying the Vulnerable Patient with Rupture-Prone Plaque. Available at: http://www.ajconline.org/article/S0002-9149(08)00684-X/fulltext
5. Ross R., et. al. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126
6. Solomon SD, Lin J, Solomon CG, et al. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 12/4/2007
7. Wang TJ, et al. Biomarkers that predicted risk of cardiovascular events. N Engl J Med 12/21/2006; 355:2631-2639.
8. Internal Medicine News. FDA Approves New Test for CHD Biomarker. Available at: http://www.internalmedicinenews.com/article/S1097-8690(03)70795-1/fulltext
9. N Engl J Med. 10/2000;343:1148-1155. Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention. Available at: http://www.ajconline.org/article/S0002-9149(08)00686-3/fulltext
10. Zacho J et al. Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease. N Engl J Med 10/30/2008; 359:1897-1908
11. KIF6 Sub-analysis of: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
12. Serruys, Patrick W.,et. al.; Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque. Circulation. 9/9/2008;118:1172-1182
13. Virmani, Renu, et. al.; Lessons From Sudden Coronary Death: A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions. Atherioscler. Thom Vasc Biol. May, 2000;20:1262-1275
14. Ridker PM, et al. Rosuvastatin to Prevent Vascualr Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 11/2008; 359:2195-2207
15. Rosenson Robert S., et al. Antiatherothrombotic Porperties of Statins: Implications for Cardiovascular Event Reduction. JAMA. May 27,1998;279 (20):1643-1650
16. Ridker PM et al. Hormone Replacement Therapy and Increased Plasma Concentration of C-Reactive Protein. Circulation. Aug,1999;100:713-716
17. Nicholls,SJ; Hazen,SL; Myeloperoxidase and Cardiovascular Disease. Arterioscler. Thromb. Vasc. Biol. 3/2005;25:1102-1111
|